UY37728A - Nuevos enlazantes peptídicos y conjugados de criptoficina, su preparación y su uso terapéutico - Google Patents
Nuevos enlazantes peptídicos y conjugados de criptoficina, su preparación y su uso terapéuticoInfo
- Publication number
- UY37728A UY37728A UY0001037728A UY37728A UY37728A UY 37728 A UY37728 A UY 37728A UY 0001037728 A UY0001037728 A UY 0001037728A UY 37728 A UY37728 A UY 37728A UY 37728 A UY37728 A UY 37728A
- Authority
- UY
- Uruguay
- Prior art keywords
- therapeutic use
- cryptoficine
- conjugated
- links
- preparation
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 229930188224 Cryptophycin Natural products 0.000 abstract 2
- 125000003636 chemical group Chemical group 0.000 abstract 2
- 108010006226 cryptophycin Proteins 0.000 abstract 2
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 abstract 2
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente revelación se refiere a compuestos de la fórmula (I): RCG1-L-P (I) en donde RCG1 representa un grupo químico reactivo que es reactivo respecto de un grupo químico presente en un polipéptido como un anticuerpo; P representa H, OH o un O activado; y L representa un ligador específico. La revelación también se refiere a cargas útiles de criptoficina, así como a conjugados de criptoficina, a composiciones que los contienen y a su uso terapéutico, en especial como agentes anticáncer. La revelación también se refiere al proceso para preparar estos conjugados.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305531 | 2017-05-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY37728A true UY37728A (es) | 2019-01-02 |
Family
ID=58873750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001037728A UY37728A (es) | 2017-05-10 | 2018-05-09 | Nuevos enlazantes peptídicos y conjugados de criptoficina, su preparación y su uso terapéutico |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20180369401A1 (es) |
| EP (1) | EP3621658A1 (es) |
| JP (2) | JP2020519610A (es) |
| KR (1) | KR20200005580A (es) |
| CN (1) | CN110831633A (es) |
| AR (1) | AR111781A1 (es) |
| AU (2) | AU2018265333C1 (es) |
| BR (1) | BR112019023336A2 (es) |
| CA (1) | CA3062977A1 (es) |
| CO (1) | CO2019012108A2 (es) |
| EA (1) | EA201992667A1 (es) |
| EC (1) | ECSP19078277A (es) |
| IL (1) | IL270507B2 (es) |
| MA (1) | MA50764A (es) |
| MX (1) | MX2019013421A (es) |
| PH (1) | PH12019550230A1 (es) |
| TN (1) | TN2019000303A1 (es) |
| TW (1) | TWI778059B (es) |
| UY (1) | UY37728A (es) |
| WO (1) | WO2018206635A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| CN111154133B (zh) * | 2020-01-03 | 2022-07-12 | 万华化学集团股份有限公司 | 一种环氧树脂发泡剂，环氧树脂组合物及环氧发泡材料的制备方法和用途 |
| CN114053426A (zh) * | 2020-07-30 | 2022-02-18 | 成都科岭源医药技术有限公司 | 一种双药链接组装单元及双药靶向接头-药物偶联物 |
| CN115105607A (zh) * | 2021-03-22 | 2022-09-27 | 成都科岭源医药技术有限公司 | 一种用于adc的双药-接头的制备方法及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ64599A3 (cs) * | 1996-08-30 | 1999-10-13 | Eli Lilly And Company | Farmaceutické sloučeniny |
| US20050175619A1 (en) | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
| USRE47123E1 (en) | 2006-07-18 | 2018-11-13 | Sanofi | EPHA2 receptor antagonist antibodies |
| FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| KR101364475B1 (ko) | 2009-06-30 | 2014-02-19 | 알까뗄 루슨트 | 무선 로컬 영역 네트워크, 관련된 액세스 제어기 및 액세스 포인트 디바이스에서 모바일 단말을 위한 로밍 방법 |
| AR078470A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | Anticuerpos que se unen especificamente al receptor epha2 |
| CA2934030A1 (en) * | 2013-10-15 | 2015-04-23 | Sorrento Therapeutics Inc. | Drug-conjugates with a targeting molecule and two different drugs |
| MX2021008464A (es) | 2013-10-15 | 2023-03-03 | Seattle Genetics Inc | Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco. |
| WO2015073575A2 (en) * | 2013-11-12 | 2015-05-21 | Centre For Probe Development And Commercialization | Residualizing linkers and uses thereof |
| WO2016065145A2 (en) | 2014-10-22 | 2016-04-28 | The Johns Hopkins University | Psma targeted reversed carbamates and methods of use thereof |
| EP3229844B1 (en) * | 2014-12-09 | 2020-03-04 | AbbVie Inc. | Antibody drug conjugates with cell permeable bcl-xl inhibitors |
| JP2018515457A (ja) * | 2015-04-21 | 2018-06-14 | アッヴィ・ステムセントルクス・エル・エル・シー | カリケアマイシン構築物および使用方法 |
| TWI714661B (zh) * | 2015-11-05 | 2021-01-01 | 法商賽諾菲公司 | 新穎念珠藻素化合物及接合物、其製備與其治療用途 |
| CN108066772B (zh) * | 2016-11-14 | 2021-07-13 | 中国科学院上海药物研究所 | 靶向tacstd2的抗体与药物偶联体(adc)分子 |
-
2018
- 2018-05-09 MA MA050764A patent/MA50764A/fr unknown
- 2018-05-09 AR ARP180101213A patent/AR111781A1/es unknown
- 2018-05-09 KR KR1020197035740A patent/KR20200005580A/ko not_active Application Discontinuation
- 2018-05-09 WO PCT/EP2018/061989 patent/WO2018206635A1/en unknown
- 2018-05-09 EA EA201992667A patent/EA201992667A1/ru unknown
- 2018-05-09 AU AU2018265333A patent/AU2018265333C1/en active Active
- 2018-05-09 JP JP2019561911A patent/JP2020519610A/ja active Pending
- 2018-05-09 TW TW107115718A patent/TWI778059B/zh active
- 2018-05-09 CA CA3062977A patent/CA3062977A1/en active Pending
- 2018-05-09 TN TNP/2019/000303A patent/TN2019000303A1/en unknown
- 2018-05-09 US US15/975,423 patent/US20180369401A1/en not_active Abandoned
- 2018-05-09 EP EP18722557.8A patent/EP3621658A1/en active Pending
- 2018-05-09 CN CN201880044816.0A patent/CN110831633A/zh active Pending
- 2018-05-09 US US16/612,090 patent/US20200093934A1/en active Pending
- 2018-05-09 MX MX2019013421A patent/MX2019013421A/es unknown
- 2018-05-09 UY UY0001037728A patent/UY37728A/es not_active Application Discontinuation
- 2018-05-09 BR BR112019023336-9A patent/BR112019023336A2/pt unknown
-
2019
- 2019-10-29 CO CONC2019/0012108A patent/CO2019012108A2/es unknown
- 2019-10-31 EC ECSENADI201978277A patent/ECSP19078277A/es unknown
- 2019-11-04 US US16/673,367 patent/US11007275B2/en active Active
- 2019-11-05 PH PH12019550230A patent/PH12019550230A1/en unknown
- 2019-11-07 IL IL270507A patent/IL270507B2/en unknown
-
2022
- 2022-06-30 AU AU2022204711A patent/AU2022204711B2/en active Active
-
2023
- 2023-04-06 JP JP2023061810A patent/JP2023085475A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018265333C1 (en) | 2023-08-17 |
| EA201992667A1 (ru) | 2020-03-10 |
| BR112019023336A2 (pt) | 2020-06-16 |
| AU2018265333A1 (en) | 2019-11-28 |
| TN2019000303A1 (en) | 2021-05-07 |
| AU2022204711B2 (en) | 2024-01-04 |
| WO2018206635A1 (en) | 2018-11-15 |
| AU2022204711A1 (en) | 2022-07-21 |
| EP3621658A1 (en) | 2020-03-18 |
| JP2020519610A (ja) | 2020-07-02 |
| CO2019012108A2 (es) | 2020-02-28 |
| IL270507B2 (en) | 2023-08-01 |
| AU2018265333B2 (en) | 2022-07-21 |
| CA3062977A1 (en) | 2018-11-15 |
| US20200093934A1 (en) | 2020-03-26 |
| IL270507B1 (en) | 2023-04-01 |
| ECSP19078277A (es) | 2019-11-30 |
| US20200054760A1 (en) | 2020-02-20 |
| US20210228726A1 (en) | 2021-07-29 |
| TWI778059B (zh) | 2022-09-21 |
| US11007275B2 (en) | 2021-05-18 |
| AR111781A1 (es) | 2019-08-21 |
| CN110831633A (zh) | 2020-02-21 |
| IL270507A (es) | 2019-12-31 |
| KR20200005580A (ko) | 2020-01-15 |
| US20180369401A1 (en) | 2018-12-27 |
| MX2019013421A (es) | 2020-02-05 |
| JP2023085475A (ja) | 2023-06-20 |
| TW201907957A (zh) | 2019-03-01 |
| MA50764A (fr) | 2020-03-18 |
| PH12019550230A1 (en) | 2020-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37728A (es) | Nuevos enlazantes peptídicos y conjugados de criptoficina, su preparación y su uso terapéutico | |
| ECSP18090693A (es) | Compuestos moduladores de fxr (nr1h4) | |
| UY38076A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
| CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
| CL2018000106A1 (es) | Moléculas de anticuerpo que se unen a cd45 | |
| UY36445A (es) | Compuestos moduladores de fxr (nr1h4 que contiene grupos hidroxi) | |
| CL2018001210A1 (es) | Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico. | |
| AR091961A1 (es) | Inmunoconjugados y anticuerpos anti-etbr (receptor de endotelina b) | |
| BR112018075166A2 (pt) | derivados de carbonucleosídeo substituídos úteis como agentes anticâncer | |
| CL2016002116A1 (es) | Anticuerpos anti-fap y métodos de utilización (divisional sol. n°369-13). | |
| BR112018068278A2 (pt) | derivado de 3-desóxi e suas composições farmacêuticas | |
| CL2012003054A1 (es) | Anticuerpos contra la angiopoyetina 2 humana (ang-2); composicion farmaceutica que contiene dicho anticuerpo; uso del anticuerpo para preparar medicamento destinado a la prevencion de metastasis; acido nucleico que codifica dicho anticuerpo; vector de expresión. | |
| AR070453A1 (es) | Anticuerpos dirigidos a angiopoyetina -1 y angiopoyetina-2 y usos de los mismos | |
| BR112015015031A2 (pt) | processo de glicoconjugação | |
| CO6541621A2 (es) | Anticuerpos que se unen preferencialmente al dominio 4 extracelular de csf 1r humano y uso de los mismos | |
| BRPI0905733B8 (pt) | composição, formulação farmacêutica, método para a produção de uma composição farmacêutica e uso de uma formulação farmacêutica | |
| AR089010A1 (es) | Anticuerpos anti-pd-l1 y sus usos | |
| BR112018068142A2 (pt) | corantes nir de alvo ca ix e seus usos | |
| BRPI0607323B8 (pt) | composições, usos de polipeptídeos e de anticorpos, bem como kits para a detecção de anticorpo que se liga especificamente a um polipeptídeo | |
| BR112012024822B8 (pt) | Composto, uso de um composto e composição farmacêutica | |
| HN2012000217A (es) | Compuestos derivados de amido espirociclicos y sales farmaceuticamente aceptable de los mismos. | |
| BR112018010535A2 (pt) | compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor | |
| CO6590210A1 (es) | Complejo obtenido a partir de mezclas de ácido hialurónico o una sal del mismo y sulfato de condroitina | |
| BR112016030983A8 (pt) | composições para o tratamento de obesidade, prevenção de ganho de peso, promoção de perda de peso, promoção de emagrecimento, ou tratamento de ou prevenção do desenvolvimento de diabetes, kit, método para a preparação de tirfostina 9 e uso | |
| AR077972A1 (es) | Anticuerpos contra cdcp1 destinados al tratamiento del cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20231103 |